Panel Urges McGhan To Recharacterize "Inflated" Complication Rates
Inamed's McGhan Medical unit should eliminate non-significant risks from its risk characterization of saline breast implants as a condition for FDA approval, the agency's General and Plastic Surgery Devices advisory panel concluded March 2 in Gaithersburg, Maryland.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
